101 related articles for article (PubMed ID: 24656733)
1. Single-nucleotide polymorphisms studied for associations with urinary toxicity from (125)I prostate brachytherapy implants.
Usmani N; Leong N; Martell K; Lan L; Ghosh S; Pervez N; Pedersen J; Yee D; Murtha A; Amanie J; Sloboda R; Murray D; Parliament M
Brachytherapy; 2014; 13(3):285-91. PubMed ID: 24656733
[TBL] [Abstract][Full Text] [Related]
2. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.
Kerns SL; Stone NN; Stock RG; Rath L; Ostrer H; Rosenstein BS
J Urol; 2013 Jul; 190(1):102-8. PubMed ID: 23376709
[TBL] [Abstract][Full Text] [Related]
3. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
Carignan D; Lessard T; Villeneuve L; Desjardins S; Magnan S; Després P; Martin AG; Foster W; Guillemette C; Lévesque É; Vigneault E
Prostate; 2020 May; 80(8):632-639. PubMed ID: 32201973
[TBL] [Abstract][Full Text] [Related]
4. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract][Full Text] [Related]
5. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.
Kukiełka AM; Dąbrowski T; Walasek T; Olchawa A; Kudzia R; Dybek D
Brachytherapy; 2015; 14(3):359-65. PubMed ID: 25736733
[TBL] [Abstract][Full Text] [Related]
7. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Burri RJ; Stock RG; Cesaretti JA; Atencio DP; Peters S; Peters CA; Fan G; Stone NN; Ostrer H; Rosenstein BS
Radiat Res; 2008 Jul; 170(1):49-59. PubMed ID: 18582155
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer.
Vuolukka K; Auvinen P; Palmgren JE; Voutilainen T; Aaltomaa S; Kataja V
Brachytherapy; 2019; 18(5):583-588. PubMed ID: 31227400
[TBL] [Abstract][Full Text] [Related]
9. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
11. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
12. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
13. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
14. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
16. [Iodine 125 prostate brachytherapy: prognostic factors for long-term urinary, digestive and sexual toxicities].
Doyen J; Chamorey E; Mohammed Ali A; Ginot A; Ferre M; Castelli J; Quintens H; Amiel J; Hannoun-Lévi JM
Cancer Radiother; 2009 Dec; 13(8):721-30. PubMed ID: 19884031
[TBL] [Abstract][Full Text] [Related]
17. Long-term urinary sequelae following 125iodine prostate brachytherapy.
Crook J; Fleshner N; Roberts C; Pond G
J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
[TBL] [Abstract][Full Text] [Related]
18. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients.
Pugh TJ; Keyes M; Barclay L; Delaney A; Krzywinski M; Thomas D; Novik K; Yang C; Agranovich A; McKenzie M; Morris WJ; Olive PL; Marra MA; Moore RA
Clin Cancer Res; 2009 Aug; 15(15):5008-16. PubMed ID: 19638463
[TBL] [Abstract][Full Text] [Related]
19. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
Thomas C; Keyes M; Liu M; Moravan V
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
